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Arterial hypotension has been demonstrated after left 
ventriculography using currently available ionic contrast 
agents. This adverse hemodynamic response is signifi•
cantly decreased with the newer nonionic contrast agents. 
Calcium channel antagonists also produce a hypotensive 
response. The potentially accentuated hypotensive re•
sponse after bolus contrast angiography in patients re•
ceiving the calcium antagonists nifedipine and diltiazem 
was evaluated. Three contrast agents were compared: 
two ionic agents (Renografin-76 and Hypaque-76) and a 
nonionic agent (iopamidol). The hemodynamic response 
after left ventriculography was assessed in 125 patients, 
65 receiving nifedipine or diltiazem and 60 not receiving 
these drugs. 
Baseline clinical characteristics were similar in all 
patient groups. The hypotensive response was signifi•
cantly greater after left ventriculography with the ionic 
agents than with the nonionic agent. In those patients 
receiving nifedipine or diltiazem, the hypotensive re-
Adverse hemodynamic changes associated with left ven•
triculography using the currently available ionic contrast 
media have been well documented (1-10). A decrease in 
systemic arterial pressure occurs as a result of peripheral 
vasodilation. A direct myocardial depressant effect has also 
been demonstrated with diminished regional and global left 
ventricular contractility, decreased left ventricular peak sys•
tolic pressure and increased left ventricular end-diastolic 
pressure and volume (1,7,11-17). Onset of these adverse 
effects may occur as early as 10 seconds and persist for 
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sponse after bolus contrast angiography using the ionic 
agents occurred earlier after contrast injection (4.2 ± 
3.1 versus 12.9 ± 6.0 seconds, p < 0.0001), was more 
profound (maximal decrease in systolic arterial pressure, 
48.5 ± 13.9 versus 36.9 ± 13.1 mm Hg, p < 0.001) 
and was more prolonged (62.3 ± 11.0 versus 36.4 ± 
12.0 seconds, p < 0.0001) than in patients not receiving 
these drugs. A comparison of the two ionic contrast agents 
showed no significant difference in the hypotensive re•
sponse. There was no difference in the hemodynamic 
response after angiography among patients receiving io•
pamidol alone and those receiving iopamidol and cal•
cium antagonists. Thus, patients receiving the calcium 
antagonists diltiazem and nifedipine and undergoing left 
ventriculography with ionic contrast agents are at added 
risk for accentuation and prolongation of the hypoten•
sive response. 
(J Am Coil CardioI1985;6:785-91) 
longer than 15 minutes after the bolus injection of ionic 
contrast medium. Hypocalcemia due to chelating agents 
added to contrast medium as stabilizing agents has been 
demonstrated after cardiovascular injection and the decrease 
in systolic arterial pressure is directly correlated with the 
severity of hypocalcemia (15,18-20). In an attempt to re•
verse the myocardial depressant reponse due to the hypo•
calcemia, calcium in the form of calcium edetate has been 
substituted for disodium edetate in several commercially 
available ionic agents (18-20). Recently, non ionic contrast 
agents have been developed and approved for myelography. 
Vascular injections in animal and human studies (21-27) 
have demonstrated significantly less adverse hemodynamic 
effects when these new nonionic agents are compared with 
the currently available ionic media. 
The hemodynamic actions of the calcium channel antag•
onists have been previously described (28,29). Single oral 
doses of diltiazem (120 mg) and nifedipine (20 mg) in nor•
mal subjects at rest result in a significant reduction in sys•
temic vascular resistance and a fall in arterial blood pressure. 
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This hemodynamic response is due to selective blocking of 
excitation coupling in arterial smooth muscle and myocar•
dium (30). The purpose of this investigation was to evaluate 
the potential additive hypotensive effects of two currently 
available calcium antagonists, nifedipine and diltiazem, with 
bolus contrast left ventriculography. In this study three con•
trast agents were evaluated: two currently available ionic 
contrast agents (Renografin-76 and Hypaque-76) and a new 
nonionic agent (iopamidol). The hemodynamic response to 
left ventriculography using each of the three contrast agents 
was evaluated and compared in a random fashion in two 
groups of patients, those receiving nifedipine or diltiazem 
and those not receiving these drugs. 
Methods 
Patient selection. All patients undergoing bolus contrast 
left ventricular angiography at the San Francisco Veterans 
Administration Medical Center were eligible for this study 
except 1) patients with a history of an adverse reaction to 
contrast media or iodinated compounds; 2) patients with 
valvular heart disease; 3) patients with creatinine clearance 
below 25 mllmin; and 4) patients receiving intravenous 
vasodilators. 
One hundred twenty-five patients were randomized to an 
ionic contrast agent, diatrizoate meglumine and diatrizoate 
sodium (Renografin-76) or diatrizoate meglumine and dia•
trizoate sodium with edetate calcium (concentration of cal•
cium, 0.267 mM) substituted for edetate dis odium as a che•
lating stabilizing agent (Hypaque-76) or a new nonionic 
contrast agent (iopamidol). Patients receiving each of these 
three contrast agents were then divided into two groups for 
comparison, those receiving a calcium antagonist, nifedi•
pine or diltiazem, and those not receiving this treatment. 
No patients in this study were receiving oral verapamil. The 
protocol was approved by the Human Research Committee 
of the University of California, San Francisco. Informed, 
written consent was obtained. 
Procedure. All patients received oral diazepam (10 mg) 
as premedication; no patient received atropine. All precath•
eterization medications were continued. Electrocardio•
graphic leads I and II were monitored continuously during 
the procedure. An 8F USCI sheath was placed in a femoral 
artery. The left ventriculogram was performed using a 7F 
Cordis high flow pigtail catheter and 0.5 mllkg body weight 
of contrast medium was injected at 12 mIls. The amount of 
contrast agent injected for the left ventriculogram was 39.8 
± 4.2 ml in the iopamidol group, 38.2 ± 5.1 ml in the 
Renografin-76 group and 41.5 ± 3.8 ml in the Hypaque-
76 group (p = NS). Left ventricular volumes and ejection 
fraction were calculated according to the method of Kennedy 
et al. (31). The electrocardiogram, left ventricular pressure 
and femoral artery pressure were recorded continuously for 
6 seconds before left ventriculography and for the initial 2 
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minutes after contrast injection at a paper speed of 100 
mm/s. No patient underwent selective injections of the right 
or left coronary artery before the left ventriculogram. 
Statistics. Hemodynamic variables were analyzed using 
repeated measures analysis of variance to determine whether 
there was a statistically significant difference among the 
changes induced by the contrast agents. A two-tailed un•
paired t test was used to compare the hemodynamic variables 
of the iopamidol, Renografin-76 and Hypaque-76 groups at 
baseline. Data in the text and tables are presented as mean 
± 1 standard deviation; mean values ± 1 standard error 
are shown in the figures. 
Results 
Patient characteristics. One hundred twenty-five pa•
tients undergoing left ventriculography before selective 
coronary angiography were evaluated. Thirty-seven patients 
(mean age, 57.4 ± 9.4 years) received iopamidol, 48 pa•
tients (mean age, 58.8 ± 6.3 years) received Renografin-
76 and 40 patients (mean age, 59.2 ± 7.3 years) received 
Hypaque-76. 
The clinical characteristics of the patients in each contrast 
agent treatment group receiving nifedipine or diltiazem com•
pared with those not receiving these drugs are listed in Table 
1. Coronary artery lesions were considered significant if 
75% or more of the cross-sectional luminal area of the vessel 
was obstructed. When the three contrast agent groups were 
compared, there was no significant difference in the severity 
of coronary artery disease. Indexes of left ventricular func•
tion are also listed in Table 1. There was no significant 
difference in ejection fraction, left ventricular end-diastolic 
volume index or baseline left ventricular end-diastolic pres•
sure among the three contrast medium groups. 
Medications other than the calcium antagonists nifedipine 
and diltiazem received by patients in each group were com•
pared. There was no significant difference in the types or 
dosages of the medications prescribed for patients in each 
of the three contrast agent groups. These included long•
acting nitrates, beta-adrenergic blocking agents, digoxin, 
antiarrhythmic agents, diuretic drugs and antihypertensive 
agents. Similarly, there was no significant difference in 
these medications or dosages prescribed between patients 
receiving nifedipine or diltiazem and those not receiving 
these drugs in each of the contrast agent groups. 
Hemodynamic changes. Baseline systolic arterial pres•
sure and heart rate for each group are listed in Table 1. 
There was no significant difference in baseline arterial pres•
sure in those patients receiving iopamidol, Renografin-76 
and Hypaque-76 (141.5 ± 23.6, 142.6 ± 17.4 and 143.3 
± 21.1 mm Hg, respectively). Similarly, there was no 
significant difference in baseline systolic arterial pressure 
between those patients receiving nifedipine or diltiazem and 
those not receiving these drugs (Table 1). 
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Table 1. Coronary Anatomy and Baseline Hemodynamic Variables in the Three Treatment Groups 
Iopamidol Renografin-76 Hypaque-76 
+ + + 
(n = 19) (n = 18) (n = 25) (n = 23) (n = 21) (n = 19) 
Severit}' of CAD (no. of Qatients with> 75% obstruction) 
No coronary 2 3 2 4 6 2 
disease 
Single vessel 5 4 3 2 
disease 
Two vessel 3 6 9 7 3 4 
disease 
Three vessel 9 8 10 II 15 11 
disease 
LMCAD 2 6 5 II 4 8 
Left Ventricular Function 
EF (%) 59.0 ± 10.2 60.6 ± 11.6 65.3 ± 13.5 59.3 ± 12.7 63.1 ± 11.4 60.7 ± 14.5 
EDVI (cc/m2) 78.4 ± 17.4 82.8 ± 20.0 76.0 ± 13.2 77.4 ± 21.4 75.3 ± 14.9 72.7 ± 18.8 
EDP (mm Hg) 13.4 ± 5.2 12.4 ± 7.9 13.7 ± 6.0 12.8 ± 4.2 13.2 ± 6.6 12.2 ± 5.3 
SAP (mm Hg) 139.3 ± 25.1 143.9 ± 22.5 143.5 ± 20.2 141.2 ± 11.8 140.5 ± 17.1 146.4 ± 24.8 
HR (beats/min) 59.6 ± 5.3 62.6 ± 7.9 62.6 ± 14.8 61.3 ± 9.2 64.6 ± 11.1 66.4 ± 12.1 
Data presented as mean ± I SD. + = patients receiving nifedipine or diltiazem; - = patients not receiving nifedipine or diltiazem; CAD = 
coronary artery disease; EDP = end-diastolic pressure; EF = ejection fraction; EDVI = end-diastolic volume index; HR = heart rate; LMCAD = left 
main coronary artery disease; SAP = systolic arterial pressure. 
After left ventriculography, there was a decrease in sys•
tolic arterial pressure in each contrast agent treatment group. 
However, there was a significantly greater hypotensive re•
sponse among those receiving Renografin-76 and Hypaque-
76 compared with those receiving iopamidol (Fig. 1 and 
Table 2). The number of patients experiencing a hypotensive 
response, defined as a fall in systolic arterial pressure greater 
than 10% of baseline, was 22 of 37 patients in the iopamidol 
treatment group compared with 48 of 48 in the Renografin-
76 group and 40 of 40 in the Hypaque-76 group. The max•
imal decrease in systolic arterial pressure was significantly 
greater among those receiving Renografin-76 and Hypaque-
76 than in those receiving iopamidol (45.8 ± 15.0 and 41.0 
± 12.5 mm Hg versus 16.2 ± 11.3 mm Hg, respectively) 
(p < 0.0005, ionic agents compared with the nonionic agent). 
The onset of the hypotensive response occurred significantly 
earlier in the Renografin-76 and Hypaque-76 treatment groups 
compared with the iopamidol treatment group (8.8 ± 5.2 
and 9.4 ± 7. 1 seconds versus 13.0 ± 5.0 seconds, re•
spectively) (p < 0.001, ionic versus nonionic). In addition, 
the duration of the hypotensive response was significantly 
longer in the Renografin-76 and Hypaque-76 treatment groups 
than in the iopamidol treatment group (49.4 ± 21. 7 and 
55.4 ± 25.9 seconds versus 5.9 ± 8.6 seconds) (p < 
0.0005, ionic versus nonionic). The diastolic arterial pres•
sure response after left ventriculography paralleled the sys•
tolic arterial response. There was a significant decrease in 
the RR interval after left ventriculography in the Renografin-
76 treatment group (baseline 998 ± 137 to 889 ± 104 ms 
at 30 seconds after injection, p < 0.001) and the Hypaque-
76 treatment group (baseline, 952 ± 144 to 815 ± 126 ms 
at 30 seconds after injection, p < 0.001). There was a mild 
decrease in RR interval after iopamidol (baseline 1,015 ± 
88 to 954 ± 83 ms at 30 seconds after injection, p < 0.01); 
however, this change was significantly less than with Reno•
grafin-76 and Hypaque-76 (p < 0.05). 
Effect of nifedipine or diltiazem. In the iopamidol 
treatment group there was no significant difference in the 
severity, time of onset or duration of the hypotensive re•
sponse between patients receiving nifedipine or diltiazem 
Figure 1. Systolic arterial pressure immediately before (time 0) 
and for 2 minutes after left ventriculography using iopamidol (A), 
Renografin-76 (e) and Hypaque 76 (_). Data are presented as 
mean ± I standard error. Using repeated measures analysis of 
variance, there was a statistically significant difference after in•
jection of iopamidol compared with Renografin-76 and Hypaque-
76 (p < 0.001) and no significant difference between Renografin-
76 and Hypaque-76. 
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Table 2. Severity and Duration of Hypotensive Response in the Three Treatment Groups 
Hypotensive response 
(no. of patients) 
Onset (seconds) 
Duration (seconds) 
Decrease in maximal 
SAP (mm Hg) 
+ 
(n = 19) 
II 
12.5 ± 7.4 
6.1 ± 7.9 
16.3 ± 9.5 
Iopamidol 
(n = IS) 
II 
13.5 ± 3.9 
5.6 ± 9.3 
IS.4 ± 11.2 
Data presented as a mean ± I SD. Abbreviations as in Table I. 
and those not receiving these drugs (Fig. 2 and Table 2). 
However, the hypotensive response after left ventriculog•
raphy in the Renografin-76 and Hypaque-76 treatment groups 
was significantly greater in patients receiving nifedipine or 
diltiazem than in patients not receiving these drugs (Fig. 3 
and 4 and Table 2). In the Renografin-76 treatment group 
(Fig. 3) and Hypaque-76 treatment group (Fig. 4), patients 
receiving nifedipine or diltiazem experienced a more pro•
found hypotensive response with a greater maximal fall in 
systolic arterial pressure. Also, the onset of the hypotensive 
response occurred significantly earlier and the duration of 
the hypotensive response lasted significantly longer than in 
those not receiving nifedipine or diltiazem. There was no 
significant difference in the hemodynamic response between 
patients receiving Renografin-76 and those receiving Hy•
paque-76. 
The mean dose of nifedipine and diltiazem was 69.7 ± 
32.3 and 277.5 ± 77.0 mg daily, respectively. Left ven•
triculography was performed 3.8 ± 0.8 hours after the last 
dose of nifedipine and 4.3 ± 1.3 hours after the last dose 
of diltiazem. There was no significant difference in hemo-
Figure 2. Differences in systolic arterial pressure from control 
values during the 2 minutes after left ventriculography with io•
pamidol. Nineteen patients in this contrast agent group were re•
ceiving long-term nifedipine or diitiazem therapy (dashed line) 
and 18 patients were not receiving these drugs (solid line). There 
was no statistically significant difference between these two patient 
groups. Data presented as mean ± I standard error. 
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25 
4.2 ± 3.S 
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36.6 ± 14.2 
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15.0 ± 6.6 
36.1 ± 9.3 
35.S ± 11.9 
dynamic response between patients receiving nifedipine and 
those receiving diltiazem. A comparison of the hemody•
namic response after contrast ventriculography between pa•
tients receiving beta-adrenergic blocking agents and those 
not receiving beta-blockers showed no significant difference. 
Discussion 
Hypotensive response after bolus contrast ventricu•
lography. Patients receiving the calcium antagonists ni•
fedipine and diltiazem and undergoing left ventriculography 
with an ionic contrast agent experienced a more severe hy•
potensive response than patients not receiving these drugs. 
The hypotensive response was more prolonged, more pro•
nounced and earlier in onset in the patients receiving ni•
fedipine or diltiazem. The hemodynamic response with Ren•
ografin-76 was similar to that with Hypaque-76. With these 
Figure 3. Differences in systolic arterial pressure from control 
values during 2 minutes after left ventriculography with Reno•
grafin-76. Twenty-five patients in this contrast agent group were 
receiving long-term nifedipine or diltiazem therapy (dashed line) 
and 23 patients were not receiving these drugs (solid line). Using 
repeated measures analysis of variance, the change in systolic 
arterial pressure in patients receiving Renografin-76 alone was 
statistically different from that in patients receiving Renografin-
76 and nifedipine or diltiazem (p < 0.(01). Statistical difference 
at individual times between patients receiving nifedipine or dilti•
azem and those not receiving these drugs: *p < 0.01 and **p < 
0.005. Data presented as mean ± 1 standard error. 
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Figure 4. Differences in systolic arterial pressure from control 
values during 2 minutes after left ventriculography with Hypaque-
76, Twenty-one patients in this contrast agent group were receiving 
long-term nifedipine or diltiazem therapy (dashed line) and 19 
patients were not receiving these drugs (solid line). Using repeated 
measures analysis of variance, the change in systolic arterial pres•
sure in patients receiving Hypaque-76 alone was statistically dif•
ferent from that in patients receiving Hypaque-76 and nifedipine 
or diltiazem (p < 0.001). Statistical difference of change in systolic 
arterial pressure at individual times between patients receiving 
nifedipine or diltiazem and those not receiving these drugs: *p < 
0.01 and **p < 0.005. Data presented as mean ± 1 standard 
error. 
two ionic contrast agents, the hypotensive response after 
cardiac angiography was more severe than it was with the 
nonionic agent iopamidol. In addition, with iopamidol there 
was no difference in the hemodynamic response observed 
between patients receiving nifedipine or diltiazem and those 
not receiving these drugs. 
The risk associated with cardiac angiography is minimal, 
the most common adverse effects being hypotension, altered 
left ventricular function and electrophysiologic changes 
including significant bradyarrhythmias and ventricular ec•
topic activity (32,33). The hypotensive effects and altered 
left ventricular function are manifested as decreased sys•
temic vascular resistance and systolic arterial pressure, de•
creased peak systolic left ventricular pressure, decreased 
maximal rate of rise in pressure (dP/dt) and increased left 
ventricular end-diastolic pressure (2,3,5,7,9-11). The cause 
of these changes is unclear; however, several potential 
mechanisms including osmolality of the contrast agent, cat•
ionic content of the agent, hypocalcemia due to added che•
lating agents and a direct effect of the contrast agent mol•
ecule have been suggested (15-20). 
Role of hypocalcemia. The role of hypocalcemia in•
duced by calcium chelating agents contained in ionic con•
trast agents as the cause of this hypotensive response has 
been evaluated (34-36). Wolpers et al. (34) demonstrated 
a decrease in calcium concentration and an alteration in 
sodium/calcium ratio in coronary sinus blood associated 
with a decrease in left ventricular contractility after injection 
of ionic contrast agents. The observed calcium chelating 
effects in their study suggested a calcium-binding effect of 
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the contrast molecule in addition to calcium binding by the 
chelating agents. Of the five contrast agents evaluated, the 
ionic agent with the greatest chelating effect was Reno•
grafin-76. Higgins and Schmidt (35) demonstrated a de•
crease in calcium concentration in coronary sinus blood after 
administration of Renografin-76 with depression of left ven•
tricular contractility. With induced systemic hypocalcemia, 
an even greater depression of left ventricular contractility 
was observed after injection of an ionic contrast medium. 
Hemodynamic effects of calcium antagonists. 
Transport of calcium through the slow channel during the 
action potential is responsible for excitation-contraction 
coupling in heart muscle (29). Inhibition of the calcium 
transport mechanism results in reduced myocardial con•
tractility. This selective inhibition of calcium transport has 
become an identifying characteristic of the calcium antag•
onists. These drugs also inhibit calcium movement into smooth 
muscle cells, reducing their ability to contract. Therefore, 
the hemodynamic consequences after administration of cal•
cium antagonists are decreased myocardial contractility, de•
creased dP/dt and decreased peak systolic pressure, in ad•
dition to peripheral vasodilation. These hemodynamic 
alterations are similar to those produced by cardiovascular 
injections of ionic contrast agents. Thus, our results dem•
onstrating that calcium antagonists potentiate the hypoten•
sive response of ionic contrast agents are not surprising. In 
this study the patients receiving nifedipine or diltiazem not 
only had a more pronounced hypotensive response, but this 
response was also significantly longer in duration and oc•
curred earlier after the contrast injection than that observed 
in patients not receiving these drugs. 
Addition of calcium to contrast medium. Previous an•
imal studies have demonstrated less severe adverse hemo•
dynamic effects when calcium was administered simulta•
neously with the ionic contrast agents. Salvesen et al. (37) 
demonstrated a direct correlation between the cardiode•
pressant effect of the ionic contrast agents and their dose 
and concentration. Tragardh et al. (19) and Popio et al. (15) 
demonsttated a similar relation. The former authors (19) 
added calcium in concentrations from 2.5 to 50 mEq/liter 
and demonstrated a linear telation between the concentration 
of added calcium and the degree of amelioration of the 
observed hypotensive response. An optimal concentration 
of 40 mEq/liter of added calcium was demonstrated. Com•
mercial attempts have been made to reverse the hypocal•
cemia occurring after administration of ionic agents. Cal•
cium edetate has been substituted in Hypaque-76 for disodium 
edetate used in Renografin-76. However, the concentration 
of calcium in Hypaque-76 is small (0.5 mEq/liter) compared 
with previous studies of added calcium (16,19,37). Thus, 
it is not surprising that no significant difference in the hemo•
dynamic changes associated with Hypaque-76 and Reno•
grafin-76 could be demonstrated after bolus left ventricu•
lography in this study. The concentration of calcium in the 
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form of calcium edetate is similar in iopamidol and Hy•
paque-76. Thus, altering the chelating agent or adding a 
small concentration of calcium in the form of calcium ed•
etate does hot appear to ameliorate the adverse hypotensive 
response with ionic contrast agents. 
Clinical implications. The potentiation of the hypoten•
sive response was observed in a group of patients receiving 
a moderate dose, 0.5 cc/kg, of contrast agent. Using this 
dose of contrast agent, there were no serious sequellae after 
bolus left ventriculography. However, if the hypotensive 
response associated with the ionic contrast agents is dose 
dependent, one could expect an even greater hypotensive 
response when a larger dose of contrast medium is used. It 
is not uncommon for doses of 0.5 to 1.0 cc/kg to be ad•
ininistered during left ventriculography (38). Various radio•
logic procedures including pulmonary angiography and bolus 
contrast aortography are performed using 1.0 to 1.5 cc/kg 
of contrast medium (38). Baseline systolic arterial pressure 
itt our patients was 142.4 ± 20.2 mm Hg. A similar hy•
potensive response in patients with lower systolic arterial 
pressure might not be tolerated as well. 
We have identified a group of patients, those receiving 
nifedipine or diltiazem, who are at added risk after bolus 
contrast angiography with ionic contrast agents. The benefits 
of nonionic contrast agents may outweigh the added cost of 
these agents in this group of patients. 
We express our appreciation to Mary Parks for her assistance in the cardiac 
catheterization laboratory and to Pat Paulson for her secretarial assistance. 
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